Uptake of the lateral flow urine LAM test in Europe and Central Asia

Author:

Kraef C.1,Yedilbayev A.2,Seguy N.2,Bentzon A.3,Podlekareva D.4,Cirillo D. M.5,van der Werf M. J.6,Kirk O.1

Affiliation:

1. Centre of Excellence for Health, Immunity and Infections (CHIP), University of Copenhagen, Copenhagen, Denmark, Department of Infectious Disease, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

2. WHO Regional Office for Europe, Copenhagen, Denmark

3. Centre of Excellence for Health, Immunity and Infections (CHIP), University of Copenhagen, Copenhagen, Denmark

4. Centre of Excellence for Health, Immunity and Infections (CHIP), University of Copenhagen, Copenhagen, Denmark, Department of Pulmonary Medicine, Bispebjerg Hospital, Copenhagen, Denmark

5. WHO Collaborating Centre in Tuberculosis Laboratory Strengthening and the TB Supranational Reference Laboratory, San Raffaele Scientific Institute, Milan, Italy

6. European Centre for Disease Prevention and Control, Stockholm, Sweden

Abstract

INTRODUCTION: Since 2015 (updated in 2019), the WHO has recommended to include the commercial lateral flow urine lipoarabinomannan TB test (LF-LAM), AlereLAM, in the diagnostic toolkit for severely ill people living with HIV.METHODS: To assess the current use and barriers to the implementation of the test, we conducted an electronic survey among national focal points and managers of TB and HIV programmes in the 53 Member States of the WHO European Region and a European network of clinicians working in TB and HIV medicine.RESULTS: In all, 45 individual responses (37 countries) were received from programme managers and focal points and 17 responses (14 countries) from clinicians. Only eight countries reported adopting LF-LAM policies, with only four currently using the AlereLAM (Armenia, Belarus, Ukraine and Uzbekistan). The most commonly reported barriers to implementing the test were the small number of eligible patients (with HIV-TB co-infections), the test not being included in the TB or HIV programme´s mandate and lack of budget allocation.CONCLUSION: Consistent with findings from high TB burden countries in Africa and Asia, the survey demonstrated that uptake of AlereLAM is almost non-existent. Addressing the identified barriers and the intrinsic limitations of the test could help to increase the use of the test.

Publisher

International Union Against Tuberculosis and Lung Disease

Subject

Infectious Diseases,Pulmonary and Respiratory Medicine

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3